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Abstract
Background: Pneumonia is responsible for approximately 230,000 deaths in Europe, annually. Comprehensive and
comparable reports on pneumonia mortality trends across the European Union (EU) are lacking.
Methods: A temporal analysis of national mortality statistics to compare trends in pneumonia age-standardised
death rates (ASDR) of EU countries between 2001 and 2014 was performed. International Classification of Diseases
version 10 (ICD-10) codes were used to extract data from the World Health Organisation European Detailed
Mortality Database and trends were analysed using Joinpoint regression.
Results: Median pneumonia mortality across the EU for the last recorded observation was 19.8 / 100,000 and 6.9 /
100,000 for males and females, respectively. Mortality was higher in males across all EU countries, most notably in
Estonia and Lithuania where the ratio of male to female ASDR was 4.0 and 3.7, respectively. Gender mortality
differences were lowest in the UK and Demark with ASDR ratios of 1.1 and 1.5, respectively. Pneumonia mortality
across all countries decreased by a median of 31.0% over the observation period. Countries that demonstrated an
increase in pneumonia mortality were Poland (males + 33.1%, females + 10.2%), and Lithuania (males + 6.0%).
Conclusions: Mortality from pneumonia is improving in most EU countries, however substantial variation in trends
remains between countries and between genders.
Background
Pneumonia, together with other lower respiratory tract
infections (LRTI), is the fourth leading cause of death
worldwide with approximately 2.38 million deaths attrib-
uted to LRTI in 2016 [1, 2]. In the European Union (EU)
, pneumonia remains the most frequent cause of death
from infection, especially in the elderly and those with
co-morbidities [3–7]. In 2014 pneumonia was respon-
sible for 118,300 deaths across the EU [8] and a previous
review reports an annual incidence of 1.08–1.7 per 1000
population in Europe [9]. An increase in pneumonia
hospital admissions, costs and potentially deaths is likely
given the ageing European population [10, 11]. Historic
data indicates that pneumonia costs approximately 10.1
billion Euros annually with likely additionally indirect
costs from time off work [6]. Pneumonia can be a primary
disease process, or may complicate and develop secondary
to another disease such as dementia, frailty or in immuno-
compromised patients. It is therefore important to be able
to differentiate potentially preventable pneumonia-related
deaths from intractable ones, often occurring as a conse-
quence of the individual’s co-morbidities. From an epi-
demiological point of view, such differentiation might
reflect overall management of potentially preventable
deaths, or disease prevention in the first instance.
Despite overall low rates in Europe, significant variation
in mortality from pneumonia exists amongst countries and
between geographic regions [10, 12]. The determinants of
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such differences are multifaceted: differences in smoking
regulations, healthcare system setup, pneumococcal
vaccination, or antibiotic resistance and regulations to
control air pollution in a region may contribute to fluctua-
tions in pneumonia incidences and mortality trends [13,
14]. The mortality variability also likely reflects variation
in underling incidence of pneumonia within a population.
Burden of co-morbidities such as COPD and HIV have
been demonstrated to be associated with increase inci-
dence of community acquired pneumonia in addition to
lifestyle factors such as smoking and high alcohol intake
[9]. An analysis of the global burden of disease indicates
that mortality from LRTI is decreasing globally [15]
and a previous report has highlighted that pneumonia
mortality has decreased by 3.8% per year between 1999
and 2013 in the United States [16]. To date, there has
been no published comparison of pneumonia mortality
trends across Europe using the tenth revision of the
International Statistical Classification of Diseases and
Related Health Problems (ICD) version 10 medical clas-
sification system.
Our primary objective was to describe patterns of
pneumonia mortality using available data from EU coun-
tries between 2001 and 2014. Our primary hypothesis
was that there would be an observable decline in
pneumonia-related mortality across EU states. To test
this hypothesis, we performed a temporal analysis of the
World Health Organisation (WHO) European Detailed
Mortality Database (EDMD) [17] and used Joinpoint
regression analysis to identify significant changes in
trends during this time-period.
Methods
Study design and data source
For this temporal analysis of national mortality statistics,
mortality data for pneumonia, as coded by the ICD-10
system, from individual states within the EU were de-
rived from the EDMD for the years 2001–2014. The
EDMD data is compiled from the larger WHO mortality
database. The WHO mortality database is produced
from national vital registration systems where the under-
lying cause of death is coded by the appropriate national
authority. The WHO analyse the quality and complete-
ness of these data and provide reports of these analyses
[18]. This approach has been used previously for similar
analyses [19, 20]. Mortality data was standardised to the
European Standard Population [21]. We included coun-
tries for analysis if they were member states of the Euro-
pean Union and had a population greater than 1 million.
We excluded any countries which were missing > 20% of
data (i.e. greater than any 3 years of missing data). The
EDMD is collated from data submitted to the WHO by
European member states, data submitted includes cause
of death, age of death, sex of individual. Separate data
on population size, numbers of males and females and
age category is also collected.
The EDMD uses both ICD-9 and ICD-10 to categorize
causes of death. For the purposes of the current investiga-
tion, we chose a priori to analyse recent trends in mortality
using only the ICD-10 classification, as the introduction of
ICD-10 changed the definition of pneumonia substantially
so that if pneumonia was the end-point in a chronic disease
process then the disease, instead of the pneumonia,
would be recorded as the underlying cause of death.
We abstracted from the database ICD-10 codes J12–18
for pneumonia, excluding influenza-related pneumonia
(J09, J10, J11), aspirational pneumonia (J69, O74, O29,
O89, P24.9) and congenital pneumonia (P23, P24.9,
P28.9).
The majority of EU member states have an estimated
level of coverage of deaths that are registered with cause
of death data of > 95% for the time periods included in
this study; the exceptions are Cyprus (> 78.2%) and
Croatia (> 94.9%). This rate is calculated by dividing actual
reporting by estimated mortality rate. Population and
birth recording in all countries exceeds 90%, as per the
WHO standard for inclusion in the database.
Data handling and statistical analysis
Country-specific and sex-specific mortality data were ab-
stracted from the WHO EDMD (url: http://data.euro.
who.int/dmdb/; date of access: February 2017) and
collated into Microsoft Excel spreadsheets. Mortality
data are expressed as age-standardised death rates
(ASDR) per 100,000 population using European Stand-
ard Population. Three-year average ASDR were calcu-
lated for the start (2001–2003) and end (2012–2014) of
the observation period to allow comparison of mortality
rates over the study period. Countries were ranked based
on 3-year average mortality at the start and end of the
observation period, and also for percentage change
across the observation period. Where countries had in-
complete data at the start or end of the observation
period, 2-year averages were used and, in one instance
(Denmark), the last year of available data was used.
Statistical trends were assessed using Joinpoint software
(Version 4.1.1.1) provided by the United States National
Cancer Institute Surveillance Research Program [22]. For
the purpose of Joinpoint analysis, imputed data was used
in a last observation carried forward manner. Joinpoint
regression analysis assesses changes in linear slope for
mortality trends over time [23] as described previously
[24]. Briefly, it assesses the overall trends in mortality and
identifies the best-fitting points where mortality rates
change significantly (significant increase or significant
decrease). The analysis initially starts with no Joinpoints
and tests for significant changes in the model with sequen-
tial addition of points where there is significant change in
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the slope of the line. Each joinpoint in the final model
indicates a statistically significant change in mortality
trend and Joinpoint software computes the Annual
Percentage Change (APC) for each piecewise trend by
means of a generalised linear model, assuming Poisson
distribution.
Post-hoc analysis
Previous reports have demonstrated worse health out-
comes in former communist countries who joined the
EU after 2004 compared with those that joined early
[20]. Countries who joined the EU prior to 2004 were
Austria, Belgium, Denmark, Finland, France, Germany,
Netherlands, Spain, Sweden and the United Kingdom
(UK). Countries who joined the EU post-2004 were
Croatia, Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Poland, Romania and Slovakia. We performed
a post-hoc analysis to assess whether the observed differ-
ences in gender-specific mortality followed this pattern.
First, we compared the raw differences and ratios in
male and female ASDR, for the time period 2012–2014,
for countries who joined pre- and post-2004 using the
Wilcoxon-Rank sum test. We then constructed linear
mixed-models to compare the ASDR ratio between the
two groups of European countries. For this analysis, we
treated ASDR ratio as the outcome and category of
European country (early vs late to join EU) as the pri-
mary exposure of interest. We checked the interaction
between country category and year of observation, and
retained the interaction in the model if p < 0.05. For lin-
ear models, we assessed model structures including
compound symmetry, auto-regressive, and unstructured.
We used Akaike information criterion (AIC) for final
model selection.
In addition to Joinpoint software, data was collated
into Microsoft Excel and analysed using SAS (Version 9.
4) and R Studio (Version 1.1.383).
Sensitivity analysis
We performed a single sensitivity analysis to assess con-
tributions of influenza virus on trends in pneumonia-
related mortality. We chose a priori to exclude from the
analysis deaths which were recorded to be secondary to
influenza as these are likely to represent a distinct
pathological phenomenon with high annual variations in
case fatality. However, we chose to perform a single sen-
sitivity analysis which included influenza-related mortal-
ity to assess for significant contributions to overall
trends. For this analysis, we included cases related to
ICD-10 definitions J09, J10, and J11 in addition to cases
for J12 – J18. We repeated the Joinpoint analysis, as de-
scribed above and the results are reported in the
Additional file 1.
Results
A total of 19 EU countries had sufficient data for analysis
for the chosen time-period; 12 countries had complete
data from 2001 to 2014, and 7 countries were missing 1 or
2 years of data. Malta and Luxembourg were excluded
from analysis due to populations fewer than 1 million citi-
zens. Bulgaria, Cyprus, Italy, Ireland, Greece, Portugal and
Slovenia were excluded due to > 20% (> 3 years) missing
data. Austria was a late adopter of ICD-10 (2002).
Median mortality across the EU for last recorded
observation was for males and females, respectively, 19.8
/ 100,000 (IQR 11.3–21.8) and 6.9 / 100,000 (IQR 5.3–
13.4). Table 1 summarises the first and last three-year
average mortality, i.e. 2001–2003 and 2012–2014 (unless
otherwise specified), of males and females for each of
the 19 countries included in the study. Figure 1 demon-
strates individual data points for each country, sex and
year. For males, the countries with the highest mortality
rates were Slovakia (37.0 / 100,000), Poland (32.5 /
100,000) and Romania (29.8 / 100,000). The highest
mortality rates for females were identified in the UK (20.
6 / 100,000), Slovakia (17.6 / 100,000) and Romania (15.
7 / 100,000). The lowest mortality rates for pneumonia
in males were demonstrated in Finland (3.3 / 100,000),
Austria (5.5 / 100,000) and Croatia (7.2 / 100,000). For
females, the lowest rates were in Finland (1.6 / 100,000),
Croatia (3.2 / 1,000,000) and Austria (3.6 / 100,000).
The percentage change between the start and end of our
observation period was calculated and is shown in Fig. 2.
The majority of the 19 countries demonstrated a decrease
in pneumonia-related mortality for both males and females
over the study period. Exceptions to this included Poland
(+ 33.1% and + 10.2%, for males and females, respectively)
and Lithuania (+ 6.0% for males) (Table 1). In addition,
pneumonia mortality across all countries declined by a
median value of - 31.0% (IQR: -21.7% - -38.3%) for males
and − 32.4% (IQR: -22.8% – -38.0%) for females, with
Finland having the largest decline of -92.2% for males
and -92.8% for females.
The trends in pneumonia mortality in individual coun-
tries between 2001 and 2014 were also analysed using
Joinpoint regression [23] (Fig. 1). ASDR declined con-
tinuously in France, Romania, Spain and Sweden, with
an estimated annual percentage change (EAPC) of -2.7%
/ -2.7%, -2.8% / -3.7%, -2.9% / -2.2%, -3.8% / -4.5%, for
males and females, respectively. The sharpest decrease
observed was in Croatia for the period 2006–2010 where
an EAPC of -26.8% and -27.4% was modelled for males
and females, respectively. Croatia also had the steepest
increase at the start of the observation period with an
EAPC of + 17.8% and + 12.6% for males and females, re-
spectively, between 2001 and 2004. Several countries, in-
cluding Austria, Belgium, Croatia, Czech Republic,
Denmark, Germany, Hungary, Latvia, Lithuania, and
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Slovakia, demonstrated an initial increasing trend in the
rate of pneumonia mortality before rates declined towards
the mid-to-end of the observation period.
Pneumonia mortality was higher in males across all
EU countries, most notably in Estonia and Lithuania
where the ratio of average male to female ASDR was 4.0
(20.6 / 5.2 per 100,000) and 3.7 (20.3 / 5.5 per 100,000),
respectively, at the end of the study period. In contrast,
countries such as the UK and Denmark showed a less
profound difference between male and female pneumo-
nia ASDR, with male to female ratios of 1.1 (6.3 / 5.6
per 100,000) and 1.5 (21.8 / 14.4 per 100,000), respect-
ively. Ratios for male to female mortality are represented
in Fig. 3. For the period 2012–2014, the male to female
mortality ratio was significantly lower for countries the
joined the EU prior to 2004 compared with those that
joined after (p < 0.001). The male to female mortality ra-
tios for countries that joined the EU prior to 2004
remained relatively stable from 1.71 (SD 0.25) in 2001 to
1.75 (SD 0.25) in 2014. This compares to countries that
joined the EU post-2004 which demonstrated a similarly
stable, albeit greater, male to female mortality ratios
from 2.34 (SD 0.91) in 2001 to 2.36 (SD 0.92) in 2014.
The linear mixed model confirmed a significant differ-
ence between the two country categories (p = 0.03).
The sensitivity analysis to assess the overall contribution
of influenza deaths revealed no significant differences in
overall pneumonia-mortality trends over the observation
period. A figure to compare trends with and without
influenza cases is provided as Additional file 1: Figure S1.
Discussion
This observational study of World Health Organisation
European Detailed Mortality Database age-standardised
mortality data found a low rate of pneumonia death
across the EU, but did highlight considerable variability
between the included countries. From years 2001 to
2014, there was a moderate decline in rates of death
from pneumonia in the majority of European countries.
This decrease is not universal, with specific exceptions
in Lithuania and Poland. Furthermore, we identified a dis-
parity in male and female mortality rates from pneumonia
in the majority of countries assessed.
Reporting the trends in pneumonia mortality in European
countries is important to allow comparison of statistical
data at an international level, to assess the effectiveness of
Table 1 The first and last three-year averages and percentage change in age standardised mortality rate for pneumonia in 19 European
countries during 2001–2014. The start represents the average of 2001–2003, and the end represents the average of 2012–2014, unless
otherwise specified. Rank for 2001–2003, 2011–2013 and % change is reported
Country Male Female
Start End % Change Start End % Change
Austria* 12.9(2) 5.50(2) −57.4(3) 8.33(6) 3.55(3) −57.41(3)
Belgium* 33.27(14) 21.09(13) −36.61(6) 19.15(14) 12.45(14) −35.01(8)
Croatia 26.48(11) 7.24(3) −72.65(2) 14.31(11) 3.15(2) −78.01(2)
Czech Republic 26.45(10) 19.80(10) −25.13(13) 15.99(13) 10.67(12) −33.31(9)
Denmark* 22.88(8) 21.78(15) −4.8(17) 14.81(12) 14.39(15) −2.82(18)
Estonia 34.39(15) 20.61(12) −40.07(5) 8.44(7) 5.19(5) −38.45(5)
Finland 41.56(18) 3.26(1) −92.16(1) 22.34(16) 1.61(1) −92.79(1)
France* 14.77(3) 10.82(5) −26.73(11) 8.20(5) 6.21(7) −24.27(14)
Germany 18.83(5) 13.79(8) −26.77(10) 11.00(8) 7.72(11) −29.81(11)
Hungary 9.34(1) 7.46(4) −20.19(15) 5.08(1) 3.72(4) −26.75(12)
Latvia 28.27(12) 21.75(14) −23.07(14) 7.15(3) 6.77(9) −5.2(17)
Lithuania 19.16(7) 20.30(11) 5.95(18) 6.01(2) 5.49(6) −8.63(16)
Netherlands* 32.12(13) 19.20(9) −40.22(4) 19.82(15) 11.94(13) −39.75(4)
Poland 24.44(9) 32.53(18) 33.1(19) 13.87(10) 15.28(16) 10.14(19)
Romania 40.95(17) 29.77(17) −27.3(9) 23.19(17) 15.67(17) −32.44(10)
Slovakia 43.29(19) 37.04(19) −14.44(16) 24.01(18) 17.61(18) −26.65(13)
Spain 16.02(4) 11.86(6) −25.96(12) 7.98(4) 6.29(8) −21.25(15)
Sweden 19.03(6) 12.37(7) −34.97(7) 11.10(9) 6.92(10) −37.68(6)
United Kingdom* 39.58(16) 25.90(16) −34.55(8) 31.89(19) 20.64(19) −35.26(7)
*For Austria, 2002–2003 were used for start of period with % change 2002–2003 vs 2012–2014. For Belgium, 2012–2013 were used for end of period with %
change 2001–2001 vs 2012–2013. For Denmark, 2012 was used for end of period with % change 2001–2003 vs 2012. For France, 2012–2013 were used for end of
period with % change 2001–2003 vs 2012–2013. For Netherlands, 2012–2013 were used with % change 2001–2003 vs 2012–2013. For the UK, 2012–2013 were
used for end of period with % change 2001–2003 vs 2012–2013
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public health measures, and support the implementation of
future interventions and initiatives. Our study aim was to
report pneumonia mortality data from all countries of the
EU that are classifying the disease using a single standar-
dised international coding system. Time since the imple-
mentation of the ICD-10 mortality coding system is
reaching 15 years in the majority of EU countries. To our
knowledge, this study is the first to analyse pneumonia
mortality trends across this study period using this system.
Unfortunately, incidence data for pneumonia mortality
across Europe is severely lacking with only the UK,
Finland and Spain having produced any precise popula-
tion data. It is known that pneumonia mortality varies
substantially between different European countries [25],
but comparison is difficult due to differences in data ac-
quisition and reporting, hospital admission criteria, and
differences in disease management. Further difficulties
arise from the lack of a universally recognised definition
that can be used to reliably diagnose pneumonia [26–28].
The absence of a productive cough, administration of pre-
diagnosis antibiotics, and the absence of a definitive diag-
nostic microbiological test can also impair the quality and
reliability of pneumonia mortality data [7, 26].
Due to difficulties in clinical diagnosis, ICD codes are
used to identify diseases and has become an international
standard for classification. This study utilises the ICD-10
coding system, which allows the identification of death
caused by a pneumonia infection and not as an end-point
of a different underlying disease process. Studies have vali-
dated the use of ICD-10 codes to retrospectively identify
pneumonia mortality and suggest its superiority to both
the previous ICD-9 system and the use of clinical signs,
symptoms and radiology [29].
Aggressive smoking cessation campaigns, the uptake
of pneumococcal and influenza vaccination strategies,
more widespread regulated use of guideline antibiotics
[30–32], as well as other advances in medical care are
expected to lead to a progressive and steady decline in
pneumonia mortality, similarly to that which has been
observed in, for example, sepsis [33], asthma [34] or ma-
ternal mortality [35]. The overall trend observed in this
study confirms this assumption, with a median decline
in pneumonia mortality of approximately 31% between
2001 and 2014. However, our study highlights consider-
able national differences in mortality rates, with a
greater than twelve-fold difference in mortality between
the countries with the highest and lowest mortality rates
(2012 to 2014 data). Additionally, pneumonia mortality
increased across the study period in countries such as
the Poland and Lithuania (males only).
Overall, there was a gender discrepancy with rates of
pneumonia mortality higher in males than in females.
This gender difference was higher throughout the obser-
vation period, typically in Eastern European countries
Fig. 1 Pneumonia mortality trends of male and females in 19 European countries. Lines represent result of Joinpoint analyses: dashed and
continuous lines for males and females, respectively. Squares (males) and circles (females) represent raw data; where symbol is absent, data has
been imputed for the respective year
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who joined the EU after 2004. These are generally
poorer with lower standards of living. The greater ratio
of male to female mortality in Eastern compared with
Western Europe may reflect higher rates of smoking in
males [36], pre-disposing individuals to respiratory dis-
ease. This is supported by previous findings that
smoking-attributable mortality is higher in Eastern Eur-
ope [37].
A rise in incidence and hospitalisation for pneumonia,
especially in elderly individuals, has been documented
across Europe [3, 7, 38, 39]. The high prevalence of
comorbidities in these populations is well documented
and has been linked to a poorer prognosis for pneumo-
nia [5, 40]. A recent review of pneumonia mortality
literature across Europe reported a number of variables
that have been shown to be associated with pneumonia
mortality, including age, the presence of a pleural effusion,
polymicrobial pneumonia, underlying disease severity,
failed initial therapy, pneumococcal infection, multilobar
infection, recent hospitalisation, impaired mental states,
and acute kidney injury [6]. Other explanations may
include exposure to social, economic or environmental
risk factors, lower standards of care and differences in
thresholds for hospital admission (i.e. differences in
whether sick patients are more or less likely to be admit-
ted between countries). All these factors could explain
why pneumonia mortality remained unchanged or
increased in some countries during the period of interest.
Several factors may contribute to the future burden of
pneumonia mortality in Europe. It is well established
that pneumonia is predominantly a disease of the elderly
and that mortality increases as quality of life decreases
for patients with advancing age [6]. The aging popula-
tion of Europe has been predicted to continue to rise
and this may result in a reversal in the overall decline
seen here with mortality rising with the age of the popu-
lation and burden of associated comorbidities [41]. How-
ever, as standards of care increase, mortality in younger
age groups may continue to decline. The emerging re-
sistance of pneumonia-related pathogens to commonly
used antibiotics has been documented across Europe,
although correlation with mortality could not be estab-
lished in a number of these studies [6]. These resistant
pathogens may lead to increasing treatment failure and
could have a significant impact on the future of
pneumonia-related mortality. The development of inter-
national guidelines for antibiotic use, the development of
new therapeutic interventions, and the implication of
Fig. 2 Ranked percentage change data comparing average of European age standardised death rate for 2001–2003 vs 2012–2014, unless
otherwise specified. For Austria, 2002–2003 were used for start of period with % change 2002–2003 vs 2012–2014. For Belgium, 2012–2013 were
used for end of period with % change 2001–2001 vs 2012–2013. For Cyprus, 2004 was used for start of period, and 2012–2013 were used for end
of period with % change 2004 vs 2012–2013. For Denmark, 2012 was used for end of period with % change 2001–2003 vs 2012. For France,
2012–2013 were used for end of period with % change 2001–2003 vs 2012–2013. For Netherlands, 2012–2013 was used with % change 2001–2003
vs 2012–2013. For Portugal, 2002–2003 were used for start of period with % change 2002–2003 vs 2012–2014. For Slovenia, 2010 was used for end of
period with % change 2001–2003 vs 2010. For the UK, 2012–2013 were used for end of period with % change 2001–2003 vs 2012–2013
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effective vaccination programmes may all influence the
future burden of pneumonia in Europe.
The main strength of this study is the overall totality
of data analysed. Specifically, we have utilised national
mortality statistics for a significant number of countries
over a long observation period. The data which is depos-
ited into the database is reported and validated at the
national level and therefore removes the possibility for
sampling error. We have included a high number of
countries across the European region in order to provide
comparisons between health systems. Our decision to
analyse trends over time within each country also helps
to minimise year-to-year variations in favour of overall
trend analysis. The monitoring and analysis of national
mortality statistics is valuable to assess various economic,
policy and health-related interventions. The results of this
investigation could, for example, help policy and decision-
makers to identify strategies to successfully reduce the
burden of pneumonia on mortality by comparing interven-
tions and their effects across various health systems. The
mortality data used in this study has been collected over a
14-year period and was obtained from a heterogeneous
cohort of countries across the WHO European Region.
Our study is limited by the accuracy of the certification of
death and disease classification across a vast number of
different countries. Potential variability in death certifica-
tion and coding of mortality may limit interpretation of
absolute mortality rates between nations. We focused on
changes in mortality rates over time and mortality trends
for interpretation. There is a paucity of evidence compar-
ing death certification for pneumonia with true cause of
death, with one study suggesting substantial discrepancy
[42]. Furthermore, it may be reasonable to assume that
accuracy of coding practices may vary over time as new
revisions of the ICD coding classification are implemented.
To facilitate the effective utilisation of its data, the WHO
reviews its mortality data for accuracy in reporting and
satisfactory coverage. A limitation of use of the ICD-10
classification is the potential underestimation of the pneu-
monia mortality burden by not including pneumonias as
an immediate or contributory cause of death. This disad-
vantage has been identified in a number of studies looking
at the mortality burden of pneumonia [32, 43]. One fur-
ther potential limitation is the influence of missing data.
We chose to exclude from our analysis countries with a
significant (i.e. > 20%) proportion of missing data and
imputed where countries had a smaller proportion of
missing data. Exclusion of these nine EU counties may
reduce the generalizability of our findings. In total, 4% of
data were imputed and it is possible, although unlikely,
that these may significantly influence the results.
Conclusion
Our study highlights a general decline in pneumonia mor-
tality in the European area over the period 2001 to 2014.
Important discrepancies between genders and geographical
regions were also identified, the reasons for which are likely
multi-factorial and may result from the interplay between
medical, social, economic and environmental factors.
Additional file
Additional file 1: Figure S1. Pneumonia mortality trends of male and
females in 19 European countries including influenza-related mortality
shown in red overlay. Lines represent result of Joinpoint analyses: dashed
and continuous lines for males and females, respectively. (DOCX 401 kb)
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